User login
ATLANTA — The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted in favor of a permissive recommendation to vaccinate males aged 9–26 years with the quadrivalent human papillomavirus vaccine.
ACIP also approved the statement that the human papillomavirus (HPV) vaccine would be most effective if given before young men become sexually active. Research has suggested that the vaccine “would be most effective if given prior to sexual debut,” said the CDC's Dr. Eileen Dunne, who presented background data and considerations for the quadrivalent HPV vaccine (Gardasil) in males.
Studies have shown that men have a similar prevalence of HPV compared with women, and that approximately 70% of men will have had vaginal sex by 19 years of age, Dr. Dunne said.
In clinical trials, the vaccine showed a 93% efficacy against HPV type 11 and 88% efficacy against HPV type 6, the two types of virus that have been associated with more than 90% of cases of genital warts in men.
The CDC's Harrell Chesson, Ph.D., presented cost-effectiveness data on male HPV vaccination, which suggested that vaccinating males would be most cost effective if HPV vaccination coverage in females was relatively low. In Dr. Chesson's model, the incremental cost per quality-of-life year gained was $47,500 for all outcomes, including cervical cancer and genital warts, if female vaccine coverage was 45% vs. $161,500 if coverage in women was 70%.
Adverse events were similar in the vaccine group vs. the placebo group. The most common adverse event was pain at the injection site, reported in 64% of the vaccine group and 53% of the placebo group.
Several studies have shown that HPV vaccination for boys and young men would be accepted by most health care providers, boys and men in the target age group, and parents, Dr. Dunne said.
The relatively high cost of the vaccine remains a challenge, at $130 per dose for private insurerers, but the estimated direct medical costs of genital warts in the United States is more than $2 million annually, Dr. Dunne said.
“Now boys and men aged 9–26 years can get the HPV4 vaccine,” Dr. Sandra Fryhofer, an internist in private practice in Atlanta, and the American College of Physicians liaison to ACIP, said in an interview. ACIP approved permissive, rather than routine, use of the vaccine, which means, she said, that the vaccine “won't be promoted” for males, “but it will be available,” and parents who ask can get it for their children.
The committee voted in favor of adding the quadrivalent HPV vaccine for males to the CDC's Vaccines for Children program.
For the latest information on ACIP vaccine recommendations, visit www.cdc.gov/vaccines/recs/acip
ATLANTA — The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted in favor of a permissive recommendation to vaccinate males aged 9–26 years with the quadrivalent human papillomavirus vaccine.
ACIP also approved the statement that the human papillomavirus (HPV) vaccine would be most effective if given before young men become sexually active. Research has suggested that the vaccine “would be most effective if given prior to sexual debut,” said the CDC's Dr. Eileen Dunne, who presented background data and considerations for the quadrivalent HPV vaccine (Gardasil) in males.
Studies have shown that men have a similar prevalence of HPV compared with women, and that approximately 70% of men will have had vaginal sex by 19 years of age, Dr. Dunne said.
In clinical trials, the vaccine showed a 93% efficacy against HPV type 11 and 88% efficacy against HPV type 6, the two types of virus that have been associated with more than 90% of cases of genital warts in men.
The CDC's Harrell Chesson, Ph.D., presented cost-effectiveness data on male HPV vaccination, which suggested that vaccinating males would be most cost effective if HPV vaccination coverage in females was relatively low. In Dr. Chesson's model, the incremental cost per quality-of-life year gained was $47,500 for all outcomes, including cervical cancer and genital warts, if female vaccine coverage was 45% vs. $161,500 if coverage in women was 70%.
Adverse events were similar in the vaccine group vs. the placebo group. The most common adverse event was pain at the injection site, reported in 64% of the vaccine group and 53% of the placebo group.
Several studies have shown that HPV vaccination for boys and young men would be accepted by most health care providers, boys and men in the target age group, and parents, Dr. Dunne said.
The relatively high cost of the vaccine remains a challenge, at $130 per dose for private insurerers, but the estimated direct medical costs of genital warts in the United States is more than $2 million annually, Dr. Dunne said.
“Now boys and men aged 9–26 years can get the HPV4 vaccine,” Dr. Sandra Fryhofer, an internist in private practice in Atlanta, and the American College of Physicians liaison to ACIP, said in an interview. ACIP approved permissive, rather than routine, use of the vaccine, which means, she said, that the vaccine “won't be promoted” for males, “but it will be available,” and parents who ask can get it for their children.
The committee voted in favor of adding the quadrivalent HPV vaccine for males to the CDC's Vaccines for Children program.
For the latest information on ACIP vaccine recommendations, visit www.cdc.gov/vaccines/recs/acip
ATLANTA — The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted in favor of a permissive recommendation to vaccinate males aged 9–26 years with the quadrivalent human papillomavirus vaccine.
ACIP also approved the statement that the human papillomavirus (HPV) vaccine would be most effective if given before young men become sexually active. Research has suggested that the vaccine “would be most effective if given prior to sexual debut,” said the CDC's Dr. Eileen Dunne, who presented background data and considerations for the quadrivalent HPV vaccine (Gardasil) in males.
Studies have shown that men have a similar prevalence of HPV compared with women, and that approximately 70% of men will have had vaginal sex by 19 years of age, Dr. Dunne said.
In clinical trials, the vaccine showed a 93% efficacy against HPV type 11 and 88% efficacy against HPV type 6, the two types of virus that have been associated with more than 90% of cases of genital warts in men.
The CDC's Harrell Chesson, Ph.D., presented cost-effectiveness data on male HPV vaccination, which suggested that vaccinating males would be most cost effective if HPV vaccination coverage in females was relatively low. In Dr. Chesson's model, the incremental cost per quality-of-life year gained was $47,500 for all outcomes, including cervical cancer and genital warts, if female vaccine coverage was 45% vs. $161,500 if coverage in women was 70%.
Adverse events were similar in the vaccine group vs. the placebo group. The most common adverse event was pain at the injection site, reported in 64% of the vaccine group and 53% of the placebo group.
Several studies have shown that HPV vaccination for boys and young men would be accepted by most health care providers, boys and men in the target age group, and parents, Dr. Dunne said.
The relatively high cost of the vaccine remains a challenge, at $130 per dose for private insurerers, but the estimated direct medical costs of genital warts in the United States is more than $2 million annually, Dr. Dunne said.
“Now boys and men aged 9–26 years can get the HPV4 vaccine,” Dr. Sandra Fryhofer, an internist in private practice in Atlanta, and the American College of Physicians liaison to ACIP, said in an interview. ACIP approved permissive, rather than routine, use of the vaccine, which means, she said, that the vaccine “won't be promoted” for males, “but it will be available,” and parents who ask can get it for their children.
The committee voted in favor of adding the quadrivalent HPV vaccine for males to the CDC's Vaccines for Children program.
For the latest information on ACIP vaccine recommendations, visit www.cdc.gov/vaccines/recs/acip